Autologous Bone Marrow Transplantation - Blog Science Connections

ABMT In CR2 57
CR INVERSION: 2/22 - 9!
MONTHS
12
Figure 2. Updated results of CBV (cyclophosphamide, BCNU [carmustine], and etoposide)
plus unpurged ABMT in second and subsequent remissions. Complete remission
inversion indicates subsequent remissions longer than the preceding ones.
12 months or longer. In two, the transplantation remission was longer than
the preceding remission, producing an inversion rate of 9%. Because the 95%
confidence limit extends from 0 to 21 %, we consider a study positive when the
inversion rate is at least 22%. According to these criteria, Yeager's and
Ramsay's studies are promising.
In our opinion, better results can be obtained when the two methods of
purging—the chemoseparation technique and a monoclonal antibody-based
technique—are combined. This combination of methods reduces the
influence of drug resistance and of antigenic heterogeneity. Therefore, we
have initiated a transplantation program for second and subsequent
remissions in which we can ultimately combine the two technologies.
Before we can do this, phase 1 studies of both chemopurging alone and of
the magnetic affinity colloid (MAC) technique need to be carried out
separately to determine the influence of both on hematopoietic recovery. In
chemopurging, the marrow cells are incubated with 4-HC plus vincristine,
inhibitory concentrations 75 and 90. The MAC technique is different for AML
and non-T-cell ALL. For AML, it employs SBA, CF1, PM81, and MY7